Donor lymphocyte infusions for acute myeloid leukaemia

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 3, 2008, Pages 455-466

  Soiffer, Robert J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukaemia; donor lymphocyte infusions; graft vs leukaemia effect

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 4; PEPTIDE VACCINE; PR1 VACCINE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ANTIGEN PRESENTATION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CROSS PRESENTATION; DONOR LYMPHOCYTE INFUSION; DRUG CYTOTOXICITY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; EVIDENCE BASED MEDICINE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; T CELL DEPLETION; WHOLE BODY RADIATION;

GRAFT VS LEUKEMIA EFFECT; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 51349157656     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.07.009     Document Type: Review

References (75)

1. Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87 (1996) 2195-2204
2. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 (1995) 2041-2050
3. Gale R.P., Horowitz M.M., Ash R.C., et al. Identical-twin bone marrow transplants for leukemia. Annals of Internal Medicine 120 (1994) 646-652
4. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
5. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in recipients of allogeneic-marrow grafts. The New England Journal of Medicine 300 (1979) 1068-1073
6. Weiden P.L., Sullivan K., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. The New England Journal of Medicine 304 (1981) 1529-1533
7. Odom L.F., August C.S., Githens J.H., et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?. Lancet 2 (1978) 537-540
8. Higano C.S., Brixey M., Bryant E.M., et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transfusion 50 (1990) 175-177
9. Collins R.H., Rogers Z.R., Bennett M., et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation. Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplantation 10 (1992) 391-395
10. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Annals of Internal Medicine 108 (1988) 806-814
11. Apperley J.F., Mauro F.R., Goldman J.M., et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase. Importance of a graft-versus-leukaemia effect. British Journal of Haematology 69 (1988) 239-245
12. Marmont A., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
13. Grogg D., Hahn S., and Erb P. CD4+ T cell-mediated killing of major histocompatibility complex class II-positive antigen-presenting cells (APC). III. CD4+ cytotoxic T cells induce apoptosis of APC. European Journal of Immunology 22 (1992) 267-272
14. Ziegler T.R., Young L.S., Benfell K., et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double- blind, controlled study. Annals of Internal Medicine 116 (1992) 821-828
15. Susskind B., Iannotti M.R., Shornick M.D., et al. Indirect allorecognition of HLA class I peptides by CD4+ cytolytic T lymphocytes. Human Immunology 46 (1996) 1-9
16. Zoumbos N.C., Djeu J.Y., and Young N.S. Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. Journal of Immunology 133 (1984) 769-774
17. Munker R., Lubbert M., Yonehara S., et al. Expression of the Fas antigen on primary human leukemia cells. Annals of Hematology 70 (1995) 15-17
18. Mackinnon S., Papadapoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86 (1995) 1261-1268
19. Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95 (2000) 67-71
20. Alyea E.P., Soiffer R.J., Canning C., et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91 (1998) 3671-3680
21. Dolstra H., Fredrix H., Preijers F., et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. Journal of Immunology 158 (1997) 560-565
22. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunological Reviews 157 (1997) 125-140
23. James E., Chai J.G., Dewchand H., et al. Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood 102 (2003) 388-393
24. Molldrem J.J., Clave E., Jiang Y.Z., et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90 (1997) 2529-2534
25. Yang X.F., Wu C.J., Chen L., et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Research 62 (2002) 5517-5522
26. Wu C.J., Biernacki M., Kutok J.L., et al. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clinical Cancer Research 11 (2005) 4504-4511
27. Yang X.F., Wu C.J., McLaughlin S., et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proceedings of the National Academy of Sciences of the United States of America 98 (2001) 7492-7497
28. Andersen M.H., Pedersen L.O., Becker J.C., et al. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Research 61 (2001) 869-872
29. Schmidt S.M., Schag K., Muller M.R., et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102 (2003) 571-576
30. van der Harst D., Goulmy E., Falkenburg J.H., et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83 (1994) 1060-1066
31. Kolb H., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
32. Porter D.L., Roth M.S., McGarigle C., et al. Induction of graft-vs-host disease as immunotherapy for relapsed chronic myelogenous leukemia. The New England Journal of Medicine 330 (1994) 100-106
33. Collins R., Shpilberg O., Drobyski W., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology 15 (1997) 433-444
34. Lee S.J., Zahrieh D., Alyea E.P., et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood 10 (2002) 2697-2702
35. Champlin R.E., Passweg J.R., Zhang M.J., et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95 (2000) 3996-4003
36. Wagner J.E., Thompson J.S., Carter S.L., et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre, randomised phase II-III trial. Lancet 366 (2005) 733-741
37. Porter D.L., Collins Jr. R.H., Hardy C., et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 95 (2000) 1214-1221
38. Alyea E.P., Kim H.T., Ho V., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biology of Blood and Marrow Transplantation 12 (2006) 1047-1055
39. Baron F., Maris M.B., Sanmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Journal of Clinical Oncology 23 (2005) 1993-2003
40. Porter D.L., Collins Jr. R.H., Shpilberg O., et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biology of Blood and Marrow Transplantation 5 (1999) 253-261
41. Choi S.J., Lee J.H., Lee J.H., et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 18 (2004) 1789-1797
42. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. Journal of Clinical Oncology 25 (2007) 4938-4945
43. Bethge W.A., Hegenbart U., Stuart M.J., et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 103 (2004) 790-795
44. Levine J.E., Braun T., Penza S.L., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. Journal of Clinical Oncology 20 (2002) 405-412
45. Takami A., Okumura H., Yamazaki H., et al. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. International Journal of Hematology 82 (2005) 449-455
46. Pollyea D.A., Artz A.S., Stock W., et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 40 (2007) 1027-1032
47. Levine J.E., Barrett A.J., Zhang M.J., et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplantation 42 (2008) 201-205
48. Meloni G., Foa R., and Vignetti M. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84 (1994) 2158-2163
49. Soiffer R.J., Murray C., Gonin R., et al. Effect of low dose interleukin-2 on disease relapse after T cell depleted allogeneic bone marrow transplantation. Blood 84 (1994) 964-971
50. Kolitz JE, Hars V, DeAngelo DJ, et al. Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients <60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808. American Society of Hematology Annual Meeting 2007; Abstract 157.
51. Nadal E., Fowler A., Kanfer E., et al. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Experimental Hematology 32 (2004) 218-223
52. Brouwer R.E., van der Hoorn M., Luiin-Nelernans H.C., et al. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Human Immunology 61 (2000) 565-574
53. Choudhury B.A., Liang J.C., Thomas E.K., et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93 (1999) 780-786
54. Schmid C., Lange C., Salat C., et al. Treatment of recurrent acute leukemia after marrow transplantation with donor cells and GM-CSF. Blood 94 (1999) 668a
55. Porter D.L., Levine J.L., Bunin N., et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107 (2006) 1325-1331
56. Molldrem J.J., Lee P.P., Wang C., et al. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Research 59 (1999) 2675-2681
57. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine 6 (2000) 1018-1023
58. Rosenfeld C., Cheever M.A., and Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 17 (2003) 1301-1312
59. Tamaki H., Ogawa H., Ohyashiki K., et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13 (1999) 393-399
60. Falkenburg J.H., Wafelman A.R., Joosten P., et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94 (1999) 1201-1208
61. Marijt E., Wafelman A., van der Hoorn M., et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica 92 (2007) 72-80
62. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes. The Lancet Oncology 2 (2001) 491-498
63. Kurago Z.B., Smith K.D., and Lutz C.T. NK cell recognition of MHC class I. NK cells are sensitive to peptide-binding groove and surface alpha-helical mutations that affect T cells. Journal of Immunology 154 (1995) 2631-2641
64. Malnati M.S., Peruzzi M., Parker K.C., et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 267 (1995) 1016-1018
65. Jiang Y.Z., Couriel D., Mavroudis D.A., et al. Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A. Immunology 87 (1996) 481-486
66. Jiang Y.Z., Barrett A.J., Goldman J.M., et al. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Annals of Hematology 74 (1997) 1-6
67. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
68. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003) 814-819
69. Hsu K., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105 (2005) 4878-4884
70. Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Journal of Clinical Oncology 23 (2005) 5675-5687
71. Meyer R.G., Britten C.M., Wehler D., et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 109 (2007) 374-382
72. Massenkeil G., Nagy M., Lawang M., et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplantation 31 (2003) 339-345
73. Ferra C., Rodriguez-Luaces M., Gallardo D., et al. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation 28 (2001) 963-968
74. Kobbe G., Fenk R., Neumann F., et al. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy 6 (2004) 532-542
75. Soiffer R.J., Alyea E.P., Hochberg E., et al. A randomized trial of CD8+ T cell depletion in the prevention of graft-vs-host disease associated with donor lymphocyte infusion. Biology of Blood and Marrow Transplantation 8 (2002) 625-632